TY - JOUR
AU - Jansson, Bo
AB - The Tn antigen (GalNAc -O-Ser/Thr) is heterogeneously synthesized by a variety of tumors and contains an epitope defined by lectins and antibodies as a cluster of GalNAc carbohydrates synthesized within a peptide sequence, which is rich in serine and/or threonine. The Tn antigen has been utilized as a target in vaccine experiments and also used as a biomarker for prognosis of different cancer forms. In this paper, we present a new monoclonal antibody, GOD3-2C4, with the clear hallmarks of an anti-Tn antibody. It was generated through somatic cell hybridization after immunization of a mouse with a tumor cell line and a Tn carrying mucin. The antibody recognizes synthetic Tn antigen and binds breast, colon, lung, ovarian and pancreas cancer. The GOD3-2C4 antibody has antibody-dependent cellular cytotoxicity activity against Jurkat cells in vitro, and for the first time, it can be shown that an anti-Tn antibody has a significant in vivo effect on a human cancer cell line grown as a xenograft in severe combined immunodeficiency mice.
TI - A new murine IgG1 anti-Tn monoclonal antibody with in vivo anti-tumor activity
JO - Glycobiology
DO - 10.1093/glycob/cwr048
DA - 2011-08-05
UR - https://www.deepdyve.com/lp/oxford-university-press/a-new-murine-igg1-anti-tn-monoclonal-antibody-with-in-vivo-anti-tumor-MWxh46a99r
SP - 1097
EP - 1107
VL - 21
IS - 8
DP - DeepDyve
ER -